Pay in 4 interest-free payments of $6.98 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Tirzepatide did receive FDA approval for OSA in December 2024 (the SURMOUNT-OSA trial), but Medicares coverage update for OSA is still being finalized as of mid-2026
To address this, there have been proposals to prioritize individuals at higher risk of premature death, aligning with ethical principles of equitable care (270)
Patient-reported reasons for GLP-1 treatment discontinuation 4 GLP-1 challenges in focus Learn more about Haleons trusted wellness solutions Fit in fiber Find out how Haleon products can help your patients with their fiber gaps
Liraglutide may be appropriate when both tirzepatide and semaglutide have been tried and failed, when insurance covers Saxenda but not other options, or when a patient needs a medication with the most extensive long-term safety data
